GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Lilly didn't just move the needle, it broke the scale. Results of a late-stage trial show that Type 2 diabetes patients using Eli Lilly's highly anticipated next-generation weight-loss drug retatrutide experienced a significant reduction in blood-sugar levels and weight loss, the drug manufacturer said last week. The drug, an injectable taken once a week, helped patients on the highest dose lose 15.3% of their body weight on average and lower their blood sugar by 1.9% over nine months. “Retatrutide delivers the ?highest levels of weight loss we've seen from an obesity drug to date,” Scotiabank analyst ?Louise Chen said, according to Reuters Sign up for The Daily Upside at no cost for premium analysis on all your favorite stocks. READ ALSO: Baker Hughes Undergoes an AI Makeover and Samsung Flexes Memory Muscle in Brawl with Heavyweight TSMC for Foundry Business Triple Threat GLP-1 drugs have upended the business and science of weight loss, with millions of Americans (appro
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Form Health Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 [Yahoo! Finance]Yahoo! Finance
- Jefferies trims Novo Nordisk target as GLP-1 pricing erosion and oral Wegovy launch uncertainty cloud first quarter [Yahoo! Finance]Yahoo! Finance
- Greater weight loss promised by higher-dose Wegovy shot, now approved by FDA [FOX News]FOX News
- iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [TheStreet.com]TheStreet.com
- iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/23/26 - Form 6-K
- 3/20/26 - Form 6-K
- 3/17/26 - Form 6-K
- NVO's page on the SEC website